T1	Disease	44 70	EGFR -mutant lung cancer ,
T2	Chemical	108 141	afatinib plus cetuximab delivered
T3	Disease	178 226	( L858R ) - induced lung adenocarcinomas delayed
T4	Disease	227 240	tumor relapse
T5	Phenotype	227 244	tumor relapse and
T6	Pharmacodynamic_phenotype	245 269	drug-resistance compared
T7	Chemical	293 294	.
R1	isAssociatedWith	Arg1:T1	Arg2:T2
R2	isAssociatedWith	Arg1:T1	Arg2:T3
R3	influences	Arg1:T1	Arg2:T4
R4	influences	Arg1:T1	Arg2:T5
R5	influences	Arg1:T1	Arg2:T6
R6	isAssociatedWith	Arg1:T1	Arg2:T7
R7	treats	Arg1:T2	Arg2:T1
R8	treats	Arg1:T2	Arg2:T3
R9	influences	Arg1:T2	Arg2:T4
R10	influences	Arg1:T2	Arg2:T5
R11	influences	Arg1:T2	Arg2:T6
R12	influences	Arg1:T2	Arg2:T7
R13	treats	Arg1:T3	Arg2:T1
R14	influences	Arg1:T3	Arg2:T2
R15	influences	Arg1:T3	Arg2:T4
R16	influences	Arg1:T3	Arg2:T5
R17	influences	Arg1:T3	Arg2:T6
R18	influences	Arg1:T3	Arg2:T7
R19	isAssociatedWith	Arg1:T4	Arg2:T1
R20	influences	Arg1:T4	Arg2:T2
R21	isAssociatedWith	Arg1:T4	Arg2:T3
R22	influences	Arg1:T4	Arg2:T5
R23	influences	Arg1:T4	Arg2:T6
R24	isAssociatedWith	Arg1:T4	Arg2:T7
R25	influences	Arg1:T5	Arg2:T2
R26	isAssociatedWith	Arg1:T5	Arg2:T3
R27	influences	Arg1:T5	Arg2:T4
R28	influences	Arg1:T5	Arg2:T6
R29	isAssociatedWith	Arg1:T5	Arg2:T7
R30	isAssociatedWith	Arg1:T6	Arg2:T1
R31	isAssociatedWith	Arg1:T6	Arg2:T2
R32	isAssociatedWith	Arg1:T6	Arg2:T3
R33	isAssociatedWith	Arg1:T6	Arg2:T4
R34	isAssociatedWith	Arg1:T6	Arg2:T5
R35	isAssociatedWith	Arg1:T6	Arg2:T7
R36	influences	Arg1:T7	Arg2:T2
R37	isAssociatedWith	Arg1:T7	Arg2:T3
R38	influences	Arg1:T7	Arg2:T4
R39	influences	Arg1:T7	Arg2:T5
R40	influences	Arg1:T7	Arg2:T6
